BioCentury
ARTICLE | Clinical News

Celldex routed after TNBC failure

April 16, 2018 7:11 PM UTC

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (2.9 vs. 2.8 months, HR=0.95, p=0.76).

Celldex plans to discontinue the candidate's development for all indications, including breast cancer and melanoma, and said it will review its pipeline...

BCIQ Company Profiles

Celldex Therapeutics Inc.

BCIQ Target Profiles

Glycoprotein NMB (GPNMB)